Trial Search Results

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Collaborator: National Cancer Institute (NCI)


  • Drug: 18F-fludeoxyglucose (18F-FDG)
  • Drug: 18F-FPPRGD2


Phase 1/Phase 2


Inclusion Criteria:

   - Provides written informed consent

   - Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and
   neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis
   treatment or treatment with other drugs that may alter angiogenesis

   - Able to remain still for duration of each imaging procedure (about one hour)

Exclusion Criteria:

   - Pregnant or nursing

   - Contraindication to MRI

   - History of renal insufficiency (only for MRI contrast administration)

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study